156 related articles for article (PubMed ID: 15046234)
1. Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis.
Tripathi D; Therapondos G; Lui HF; Johnston N; Webb DJ; Hayes PC
Am J Gastroenterol; 2004 Feb; 99(2):390-4. PubMed ID: 15046234
[TBL] [Abstract][Full Text] [Related]
2. Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease.
Agasti AK; Mahajan AU; Phadke AY; Nathani PJ; Sawant P
J Dig Dis; 2013 May; 14(5):266-71. PubMed ID: 23280243
[TBL] [Abstract][Full Text] [Related]
3. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
Schneider AW; Kalk JF; Klein CP
Hepatology; 1999 Feb; 29(2):334-9. PubMed ID: 9918907
[TBL] [Abstract][Full Text] [Related]
4. Losartan in preascitic cirrhosis.
Castaño G; Viudez P; Sookoian S
Am J Gastroenterol; 2004 Nov; 99(11):2282-3. PubMed ID: 15555016
[No Abstract] [Full Text] [Related]
5. Portal pressure response to losartan compared with propranolol in patients with cirrhosis.
De BK; Bandyopadhyay K; Das TK; Das D; Biswas PK; Majumdar D; Mandal SK; Ray S; Dasgupta S
Am J Gastroenterol; 2003 Jun; 98(6):1371-6. PubMed ID: 12818283
[TBL] [Abstract][Full Text] [Related]
6. A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients.
Castaño G; Viudez P; Riccitelli M; Sookoian S
Ann Hepatol; 2003; 2(1):36-40. PubMed ID: 15094704
[TBL] [Abstract][Full Text] [Related]
7. Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats.
Heller J; Shiozawa T; Trebicka J; Hennenberg M; Schepke M; Neef M; Sauerbruch T
Eur J Clin Invest; 2003 Nov; 33(11):1006-12. PubMed ID: 14636305
[TBL] [Abstract][Full Text] [Related]
8. A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension.
Sookoian S; Castaño G; García SI; Viudez P; González C; Pirola CJ
Am J Gastroenterol; 2005 Mar; 100(3):636-42. PubMed ID: 15743363
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis.
González-Abraldes J; Albillos A; Bañares R; Del Arbol LR; Moitinho E; Rodríguez C; González M; Escorsell A; García-Pagán JC; Bosch J
Gastroenterology; 2001 Aug; 121(2):382-8. PubMed ID: 11487547
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension.
Schepke M; Werner E; Biecker E; Schiedermaier P; Heller J; Neef M; Stoffel-Wagner B; Hofer U; Caselmann WH; Sauerbruch T
Gastroenterology; 2001 Aug; 121(2):389-95. PubMed ID: 11487548
[TBL] [Abstract][Full Text] [Related]
11. Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study.
Schepke M; Wiest R; Flacke S; Heller J; Stoffel-Wagner B; Herold T; Ghauri M; Sauerbruch T
Am J Gastroenterol; 2008 May; 103(5):1152-8. PubMed ID: 18422814
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension.
Debernardi-Venon W; Barletti C; Alessandria C; Marzano A; Baronio M; Todros L; Saracco G; Repici A; Rizzetto M
Dig Dis Sci; 2002 Feb; 47(2):401-4. PubMed ID: 11855558
[TBL] [Abstract][Full Text] [Related]
13. Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis.
Girgrah N; Liu P; Collier J; Blendis L; Wong F
Gut; 2000 Jan; 46(1):114-20. PubMed ID: 10601066
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy.
Wagatsuma Y; Naritaka Y; Shimakawa T; Kanako H; Keiichiro I; Shunichi S; Konno S; Katsube T; Ogawa K
Hepatogastroenterology; 2006; 53(68):171-4. PubMed ID: 16608017
[TBL] [Abstract][Full Text] [Related]
15. Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis.
Chiang HT; Cheng JS; Lin M; Tseng WS; Chang JM; Lai KH
J Gastroenterol Hepatol; 1995; 10(3):256-60. PubMed ID: 7548800
[TBL] [Abstract][Full Text] [Related]
16. The effect of valsartan, an angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in liver cirrhosis.
Fierbinteanu-Braticevici C; Dragomir P; Tribus L; Negreanu L; Bengus A; Usvat R; Andronescu D
J Gastrointestin Liver Dis; 2006 Dec; 15(4):337-42. PubMed ID: 17205144
[TBL] [Abstract][Full Text] [Related]
17. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
Bishnu S; Ahammed SM; Sarkar A; Hembram J; Chatterjee S; Das K; Dhali GK; Chowdhury A; Das K
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):54-59. PubMed ID: 29099421
[TBL] [Abstract][Full Text] [Related]
18. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension.
Croquet V; Moal F; Veal N; Wang J; Oberti F; Roux J; Vuillemin E; Gallois Y; Douay O; Chappard D; Calès P
J Hepatol; 2002 Dec; 37(6):773-80. PubMed ID: 12445418
[TBL] [Abstract][Full Text] [Related]
19. Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity.
Baik SK; Park DH; Kim MY; Choi YJ; Kim HS; Lee DK; Kwon SO; Kim YJ; Park JW; Chang SJ
J Gastroenterol; 2003; 38(12):1150-4. PubMed ID: 14714252
[TBL] [Abstract][Full Text] [Related]
20. Effect of 1-week losartan administration on bile duct-ligated cirrhotic rats with portal hypertension.
Yang YY; Lin HC; Huang YT; Lee TY; Hou MC; Lee FY; Liu RS; Chang FY; Lee SD
J Hepatol; 2002 May; 36(5):600-6. PubMed ID: 11983442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
